Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Revenue (2023 - 2025)

Historic Revenue for Immunome (IMNM) over the last 3 years, with Q2 2025 value amounting to $4.0 million.

  • Immunome's Revenue rose 6983.93% to $4.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 444.27%. This contributed to the annual value of $9.0 million for FY2024, which is 3550.44% down from last year.
  • Per Immunome's latest filing, its Revenue stood at $4.0 million for Q2 2025, which was up 6983.93% from $2.9 million recorded in Q1 2025.
  • Immunome's 5-year Revenue high stood at $4.3 million for Q2 2023, and its period low was $1.0 million during Q1 2024.
  • Its 3-year average for Revenue is $3.0 million, with a median of $2.9 million in 2024.
  • In the last 5 years, Immunome's Revenue crashed by 5647.21% in 2024 and then surged by 18435.37% in 2025.
  • Over the past 3 years, Immunome's Revenue (Quarter) stood at $3.8 million in 2023, then dropped by 28.44% to $2.7 million in 2024, then skyrocketed by 46.64% to $4.0 million in 2025.
  • Its Revenue stands at $4.0 million for Q2 2025, versus $2.9 million for Q1 2025 and $2.7 million for Q4 2024.